Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
about
Management of hemophilia in Korea: the past, present, and future.Treatment of hemophilia B: focus on recombinant factor IX.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.Monitoring rFVIII prophylaxis dosing using global haemostasis assays.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sImpact of being underweight or overweight on factor VIII dosing in hemophilia A patients.A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patientsImproved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.Evidence of clinically significant extravascular stores of factor IX.The hope and reality of long-acting hemophilia products.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Prophylaxis in real life scenarios.Methods for individualising factor VIII dosing in prophylaxis.Various regimens for prophylactic treatment of patients with haemophilia.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.The current status of prophylactic replacement therapy in children and adults with haemophilia.Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis C.2017 Clinical trials update: Innovations in hemophilia therapy.Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.New therapies for hemophilia.Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.Hemophilia in Sports: A Case Report and Prophylactic Protocol.Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.European retrospective study of real-life haemophilia treatment.
P2860
Q34302456-97F9DB95-0629-49D8-BC13-7753F30F41C6Q34329068-A2BCB250-D4CC-4744-B3EF-57A6CA0794E8Q34503723-01C60DCB-C2CF-4BDC-B6DC-14CF97252EE1Q35766551-D7F38B2D-BE26-443C-A40E-2ACD7A26A8A4Q36189452-E2F2739E-033D-418C-A514-ADE9050B1605Q36250920-D3E59DD4-7C9C-48E0-B267-049FAB4578D2Q36380181-976FEC40-3244-4A69-A8E8-E847D3316745Q36788113-565169FA-D57A-4952-885C-39A8D2666831Q36912731-B522A356-4A51-4F13-9D89-0A8C24879C14Q37059203-2727E4F6-CF84-46F7-B347-D7656BE25280Q37098836-3E420466-D4D8-48A9-A270-B9077069B891Q37144921-DDF39B59-1A22-455E-8D41-F16435F805CDQ37304104-1376FCB5-A25A-4804-B751-18E1D3A963E0Q37591452-9B713344-556C-4240-A017-D5213DDB5794Q37626502-09245B6D-0CA8-4F31-A2B8-359917310A0DQ37990479-697239E5-05A3-4198-8BB5-566C3579FAFDQ38008021-5DA7477E-7761-454B-87F7-AA0E2BF120B8Q38079624-03E465A7-8979-4890-AE0F-766043AB8F69Q38115812-F0859EA2-2836-40C5-BEC1-EEC0BF680812Q38127745-C598096E-49E0-4238-B1B0-56622B9AD86BQ38203021-81040460-A1C2-4B87-8741-2EFCC2421297Q38203350-02731B01-EA9C-40BE-BAF2-80CBE6844839Q38205211-64376041-529B-4924-8B91-C2482E0BF3C8Q38206859-C61CA491-467C-4331-818A-AA9A39536FC3Q38222572-EA3E209D-58FD-43BC-AEF0-6B982749A224Q38308200-924E1E9E-203F-48A1-9CC0-BD4713F99293Q38371071-0B60A68D-FCE9-4FAB-A624-AAE7F159E005Q38394904-A74A3FAF-4169-457D-934A-AD9695CF1FCFQ38418489-9CAE71D0-4C69-49D3-B0E5-6B5943436E42Q38560884-661BFBD7-FB3F-41BE-8066-4300BDB20E2AQ38705742-973C41CA-E998-484A-AB79-65A9D6CF29DEQ38867485-0A5F9796-DAC9-4416-A215-B629C177549DQ38894158-30C86CFD-2506-42A6-A258-9A97285ACDDBQ38937725-191505DA-B8AA-48AC-9790-326C59BA78E3Q38950839-81A380D8-02B9-4B5B-A52B-F6290DD33E66Q39027887-EAE6B905-F26B-44F2-8930-2A31287FAB64Q39074627-59B5BEE2-6A42-4FB8-81DA-77D856EB1A62Q39174299-A8AAE315-8A40-4909-B13D-EFC8809A889AQ39252827-CDFD585A-1DD2-425E-A3FA-B1BC1DD522CDQ39268322-7B935C4B-3BD4-4456-9002-D97D42087E39
P2860
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Implications of coagulation fa ...... ctic treatment of haemophilia.
@en
Implications of coagulation fa ...... ctic treatment of haemophilia.
@nl
type
label
Implications of coagulation fa ...... ctic treatment of haemophilia.
@en
Implications of coagulation fa ...... ctic treatment of haemophilia.
@nl
prefLabel
Implications of coagulation fa ...... ctic treatment of haemophilia.
@en
Implications of coagulation fa ...... ctic treatment of haemophilia.
@nl
P2093
P2860
P921
P1433
P1476
Implications of coagulation fa ...... ctic treatment of haemophilia.
@en
P2093
International Prophylaxis Study Group Pharmacokinetics Expert Working Group
P W Collins
S Björkman
V S Blanchette
P2860
P356
10.1111/J.1365-2516.2010.02370.X
P577
2010-08-22T00:00:00Z